Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine

Inclusion Criteria: * Healthy infants and children 6-23 months of age at enrollment as determined by medical history, physical examination and clinical judgment of the investigator * Birth weight ≥ 2500 g * ≥ 37 weeks of pregnancy or judge to be full-term by the midwife or birth attendant * Parents aged 18 years and above and legal guardians aged 21 years and above as per the legal authorization in the Philippines, who have voluntarily given informed consent * Parents/ legal guardians willing to follow the study procedures of the study and available for the entire duration of the study Exclusion Criteria: * Child with a congenital abnormality * Subject with abnormal routine biological values at screening * Subject concomitantly enrolled or scheduled to be enrolled in another trial * Acute illness, in particular infectious disease or fever (axillary temperature ≥37.5°C), within three days prior to enrolment and vaccination * Known history of immune function disorders including immunodeficiency diseases, or chronic use of systemic steroids (\>20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs * Child with a previously ascertained or suspected disease caused by S. typhi * Child who have had household contact with/and or intimate exposure to an individual with laboratory-confirmed S. typhi * Known history or allergy to vaccines or other medications * Know history of allergy to eggs, chicken protein, neomycin and formaldehyde * History of uncontrolled coagulopathy or blood disorders * Mother has known HIV infection or other immune function disorders * Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the subject and interfere with the assessment of the study objectives * Child whose parents or legal guardian planning to move from the study area before the end of study period